NewAmsterdam’s CETP renaissance gathers pace
pharmaphorum
JANUARY 18, 2023
The ROSE2 study found that obicetrapib was able to reduce LDL cholesterol (LDL-c) levels when added to high-intensity statin therapy, raising the prospect that it could help patients struggling to manage their cholesterol levels with current drug therapy.
Let's personalize your content